HiberGene

Making Molecular Diagnostics Accessible

HiberGene Diagnostics Limited is a private Irish company operating in the $57 billion in-vitro diagnostics market. The company is focussed on applying molecular technology to the infectious disease segment of the diagnostic market.

Company Overview

Hibergene was established in 2009, following the discovery by doctors at the Royal Victoria Hospital that a novel rapid amplification platform could be used to detect the presence of meningitis. Having tested the platform in a hospital setting, the company is now developing a diagnostic which can be used to test for the presence of the two most common forms of the disease; Meningococcus and Pneumococcal Meningitis.

HiberGene

HiberGene is a diagnostics company utilising the latest medical technology to develop, market and manufacture diagnostic tests for human infectious diseases. Using a novel rapid amplification platform, HiberGene has developed a rapid and highly sensitive diagnostic test for meningitis.

Company History

November 2009 - HiberGene Diagnostics Limited incorporated, founded by Brendan Farrell & Peter Kidney and three doctors from the Royal Victoria Hospital in Belfast: Professor Peter Coyle, Dr Derek Fairley and Dr Joe Kidney
December 2010 - Belfast Trust announce the development by the Royal Victoria Hospital of a rapid DNA test for Meningitis and submit patent applications
October 2011 - Agreement to purchase Meningitis LAMP Patent and know-how from Belfast Trust
November 2011 - HiberGene classified as High Potential Start Up Company by Enterprise Ireland and approved for feasibility grant aid
September 2012 - HiberGene selects KPMG Corporate Finance as corporate finance advisors
October 2012 - HiberGene selects Genie reader from Optigene as instrument of choice
April 2013 – US Patent for Meningitis granted.
February 2014 - HiberGene agrees licence terms with Eiken Chemical company for LAMP technology
May 2014 - HiberGene agrees commercial terms for the licensing of Group B Streptococcus (GBS) with RVH Belfast & Queens University

Products

LAMP Technology
HG SWIFT
HG MENINGOCOCCUS
HG GBS

Leadership and Expertise in Infectious Disease Diagnostics

Professor Peter Coyle and Dr. Derek Fairley, alongside the RVH Belfast team, have developed advanced diagnostic solutions, focusing on meningitis detection. Their collaboration with Queen’s University and the Belfast Trust aims to refine technologies like the rapid DNA test for human infectious diseases. These efforts have led to the creation of innovative products that are crucial for diagnosing conditions such as meningococcus and pneumococcal meningitis.

Advancements in Diagnostic Technology and Market Expansion

HiberGene Diagnostics, founded by Brendan Farrell, is at the forefront of utilizing novel amplification technology to develop highly sensitive diagnostic tests. Through strategic commercial terms with Eiken Chemical and agreements to expand its market reach, HiberGene aims to revolutionize diagnostics. Their LAMP technology, used in rapid meningitis testing, is set to transform the diagnostic segment, supported by grants from Enterprise Ireland and collaboration with experts in the field.